Immunoforge specializes in novel drug development with pipelines based on half-life extension platform technology.
Millions of patients are suffering from thousands of rare diseases and hundreds of new intractable disorders are diagnosed every year around the world. We can challenge the development of rare disease treatments with cutting-edge technology and a sense of mission and passion. Our motivation is to meet the unmet needs in patients with rare diseases with more tolerable and effective long-term treatment.
We aim to develop first-in-class global drugs with a high probability of success through detailed action plans in candidate selection, preclinical and clinical development, and product approval.
Cutting-edge science and technology are our raw materials, and experience and passion are our tools. We believe that our endeavours will provide a lifeline to those with potentially fatal diseases and enhance the quality of life for those living with chronic conditions. We would like to express our gratitude to all those who care and support us. Your support makes us more passionate. For a better world, we will work harder.
Acquisition of patents and key assets including ELP platform and pipelines from U.S. Bio company
KF1601 received Orphan Drug Designation (ODD) from US FDA
Grant from Korean Ministry of Health and Welfare’s Biohealth Investment Infrastructure-linked R&D project (1.3 billion won)
PF1801 DMD FDA P2a IND approval
Material Transfer Agreement with Korea Univ (pH-sensitive Fc variant)
Company Headquarters relocation (Seoul National Univ > Gasan Digital Complex)
21 billion KRW (approx. 19M USD) raised for Series-B funding
PF1801 receives US FDA ODD for PM indication
Selected for Industrial-Academic Research Institute Collaboration Project (500 million KRW) (approx. 450K USD)
US Office established (Vice President Dr. Jim Ballance)
Underwriter selection (KB Securities)
PF1801 receives US FDA ODD for DMD indication
Raises 6 billion KRW for Bridge funding (approx. 5.4M USD)
Selected for The Ministry of Trade, Industry and Energy's global investment-linked technology development project (1.9 billion KRW) (approx. 1.6M USD)
Selected as a participant in the Kinase Inhibitor project of the Daegu Gyeongbuk Advanced Medical Industry Promotion Foundation.
DMD P2a Clinical trial IND submission to FDA
Selected as a participant in the Polymyositis project of the Ministry of Health and Welfare. (1.6 billion won) (approx. 1.3M USD)
Signed a technology transfer contract with Ewha Woman's University (anti-OSCAR, antibody for osteoarthritis treatment)
Selected as a participant in stepping stone project of Ministry of SMEs and Startups (PF1802)
Selected as a participant in a new drug development project of Korea Drug Development Fund (KDDF) 3 billion KRW (approx. $2.7M)
Selected as a participant in stepping stone project of Ministry of SMEs and Startups (RET inhibitor)
Selected as a participant in the candidate substance optimization project of the Daegu-Gyeongbuk New Drug Development Center (KF1601)
Transfer Kinase Inhibitors library patented technology (Daegu Gyeongbuk Advanced Medical Industry Promotion Foundation / Gachon University)
Venture certification & Corporate Research Institute certification
Government TIPS program agreement
(development of sarcopenia treatment) (PF1801)
Attracted investment from Hugel
Acquired a patent for sarcopenia (Gachon University)